Artificial intelligence has shifted from hype to reality in drug discovery, compressing timelines that once spanned a dozen years into a fraction of that and cutting R &D costs by double-digit percentages. Germany, already Europe’s largest life-sciences market, is emerging as a focal point for this transformation thanks to its strong research infrastructure, generous R &D incentives, and a fast-growing cluster of AI health-tech startups.